In Focus: Fill and finish

Viral vectors are transforming how we treat diseases. These delivery systems possess the unique ability to deliver therapeutic genes directly into cells, enabling the development of advanced vaccines and regenerative therapies. However, the very biological nature that makes viral vectors so powerful also creates extreme vulnerabilities during manufacturing.

In this In Focus feature, Sartorius (Göttingen, Germany) has partnered with us to share their expertise on fill and finish, exploring the critical risks and mitigations involved in this risk-sensitive step in viral vector manufacturing.

Infographic

Inside viral vector fill and finish: a visual guide to risk and control points

This infographic explores the unique challenges of viral vector manufacturing, particularly the critical risks that emerge during the fill-finish stage. As the most risk-sensitive step in the process, the end-to-end fill-finish workflow follows carefully controlled procedures designed to maintain product quality and aseptic conditions. This final stage serves as the critical juncture where product quality, sterility and regulatory compliance intersect – making it essential to prevent batch compromise and costly processing delays.

Resources

Interactive guide | Future-proof your fill & finish

This resource brings together a streamlined workflow overview, practical insights from EU GMP Annex 1 and perspectives from Sartorius experts.

Webinar | Stories from the field: supporting critical steps in Fill & finish

In this on-demand webinar, Sartorius experts and collaborators share real-world stories and practical insights into how our global and local Fill & Finish team supports our partners at every step.

In association with Sartorius.